These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16216149)

  • 1. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence.
    O'Brien CP
    Curr Psychiatry Rep; 2005 Oct; 7(5):327-8. PubMed ID: 16216149
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.
    Garbutt JC; Kranzler HR; O'Malley SS; Gastfriend DR; Pettinati HM; Silverman BL; Loewy JW; Ehrich EW;
    JAMA; 2005 Apr; 293(13):1617-25. PubMed ID: 15811981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release intramuscular naltrexone: a viewpoint by Falk Kiefer.
    Kiefer F
    Drugs; 2006; 66(13):1752-3. PubMed ID: 16978039
    [No Abstract]   [Full Text] [Related]  

  • 4. Extended-release intramuscular naltrexone: a viewpoint by Henry R Kranzler.
    Kranzler HR
    Drugs; 2006; 66(13):1753-4. PubMed ID: 16978038
    [No Abstract]   [Full Text] [Related]  

  • 5. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence.
    Johnson BA
    Expert Opin Pharmacother; 2006 Jun; 7(8):1065-73. PubMed ID: 16722816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naltrexone: Not Just for Opioids Anymore.
    Sudakin D
    J Med Toxicol; 2016 Mar; 12(1):71-5. PubMed ID: 26546222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alcohol dependence and mental adaptation disorders (the use of injectable extended-release naltrexone)].
    Agibalova TV; Rychkova OV; Kuznetsov AG; Gurevich GL; Val'chuk DS; Petrov AD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(6 Pt 2):63-8. PubMed ID: 23887471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
    Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
    Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release intramuscular naltrexone: a viewpoint by Steven Siegel.
    Siegel S
    Drugs; 2006; 66(13):1752. PubMed ID: 16978040
    [No Abstract]   [Full Text] [Related]  

  • 10. Vivitrex (Alkermes/Cephalon).
    Heading CE
    Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence.
    Anton RF
    Pharmacogenomics; 2008 Jun; 9(6):655-8. PubMed ID: 18518841
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-acting injectable naltrexone for the treatment of alcohol dependence.
    Mannelli P; Peindl K; Masand PS; Patkar AA
    Expert Rev Neurother; 2007 Oct; 7(10):1265-77. PubMed ID: 17939765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to maximize the efficacy of naltrexone for alcohol dependence.
    O'Malley SS
    NIDA Res Monogr; 1995; 150():53-64. PubMed ID: 8742772
    [No Abstract]   [Full Text] [Related]  

  • 14. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
    Lobmaier PP; Kunøe N; Gossop M; Waal H
    CNS Neurosci Ther; 2011 Dec; 17(6):629-36. PubMed ID: 21554565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone for the management of alcohol dependence.
    Anton RF
    N Engl J Med; 2008 Aug; 359(7):715-21. PubMed ID: 18703474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.
    Goonoo N; Bhaw-Luximon A; Ujoodha R; Jhugroo A; Hulse GK; Jhurry D
    J Control Release; 2014 Jun; 183():154-66. PubMed ID: 24704710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone (vivitrol)--a once-monthly injection for alcoholism.
    Med Lett Drugs Ther; 2006 Jul; 48(1240):63-4. PubMed ID: 16874283
    [No Abstract]   [Full Text] [Related]  

  • 18. Should Long-Acting Depot Intramuscular Naltrexone Be Prescribed Every 3 Weeks for Alcohol Use Disorder?
    Luvisi J; Ahonen K; Sethi R
    Prim Care Companion CNS Disord; 2019 May; 21(3):. PubMed ID: 31106994
    [No Abstract]   [Full Text] [Related]  

  • 19. A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence.
    Pettinati HM; Kampman KM; Lynch KG; Dundon WD; Mahoney EM; Wierzbicki MR; O'Brien CP
    Am J Addict; 2014; 23(6):591-7. PubMed ID: 25251201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Holidays, triggers, and willpower--is there a role for medications? A commentary on "The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients".
    Rosenbloom DL
    J Subst Abuse Treat; 2009 Jan; 36(1):7. PubMed ID: 19038694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.